RNU6-229P

Across TCGA pan-cancer cohorts, RNU6-229P RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RNU6-229P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RNU6-229P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-229P expression acts as an unfavorable survival marker, although some lineages such as ESCA show a favorable association.

LIHC, THCA, and GBM are the cancer types where RNU6-229P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	II,III,IV	0.051	0.716	<.001	72	view →
THCA	OS	Tertile	All	0.723	0.983	<.001	54	view →
GBM	OS	Tertile	All	0.069	0.415	<.001	36	view →
LUAD	DFS	Tertile	III,IV	0.206	0.670	.015	27	view →
SKCM	OS	Tertile	IV	0.179	0.755	<.001	18	view →
PAAD	OS	Tertile	All	0.138	0.590	<.001	18	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →
ESCA	DFS	Tertile	III,IV	0.614	0.284	.041	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RNU6-229P–LIHC (OS)

Open the LIHC breakdown →